Efficacy and Tolerability of a new Inhibitor of Thymidylate Synthase: ‘Tomudex’ (Raltitrexed)

August D.A. , Ottow R.T. , Sugarbaker P.H. : Clinical perspectives of human colorectal cancer metastases. Cancer Metastases Rev., 3: 303–324, 1984.

Moertel C.G. : Chemotherapy for advanced colorectal cancer. N. Engl. J. Med., 330: 1136–1141, 1994.

Ross P. , Heron J. , Cunningham D. : Cost of treating advanced colorectal cancer: a retrospective comparison of treatment regimens. Eur. J. Cancer, 32A (suppl. 5): S13–S17, 1996.

Scheithauer W. , Rosen H. , Kornek G.V. , Sebasta C. , Depisch D. : Randomised comparison of fluorouracil and leucovorin therapy versus fluorouracil, leucovorin and cisplatin therapy in patients with advanced colorectal cancer. Br. Med. J., 306: 752–755, 1993.

Seitz J.F. , Cunningham D. , Rath U. , Olver I.N. , Van Cutsem E. , Kerr D. , Svensson C. , Perez Manga G. , Harper P. , Zalcberg J. , Lowery K. , Azab M. for the ‘Tomudex’ study group. Final results and survival data of a large randomised trial of ‘Tomudex’ in advanced colorectal cancer (ACC) confirm comparable efficacy to 5-fluorouracil plus leucovorin (5FU+LV). Proc. Am. Soc. Clin. Oncol., 15: 201, 1996.

Topham C. St. Luke's Hospital, Guildford, UK, personal communication.

Zalcberg J. , Cunningham D. , Green M. , Francois E. , Van Cutsem E. , Schornagel J. , Adenis A. , Seymour L. , Azab M. , for the ‘Tomudex’ Colorectal Cancer Study Group. The final results of a large phase II study of the potent thymidylate synthase inhibitor Tomudex (ZD1694) in advanced colorectal cancer. J. Clin. Oncol., 14: 716–721, 1996.

Zeneca Ltd., data on file.